Q2 Earnings Estimate for SCTX Issued By HC Wainwright

Key Points

• HC Wainwright projected a Q2 2026 loss of $6.20 per share for Scribe Therapeutics and maintained a Buy rating with a $60 price target. It also forecast a $6.72 per-share loss for full-year 2026.
• Analyst sentiment remains positive, with four Buy ratings and a consensus rating of Buy; the average price target is $51.75, with targets ranging from $37 to $60.
• SCTX opened at $29.00 after trading down 5%, while insiders purchased more than 3.7 million shares worth approximately $56.3 million over the past three months.

Scribe Therapeutics Inc. (NASDAQ:SCTX - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Scribe Therapeutics in a research report issued to clients and investors on Monday, August 31st. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($6.20) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Scribe Therapeutics' Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.05) EPS, FY2026 earnings at ($6.72) EPS, Q1 2027 earnings at ($1.10) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($1.36) EPS and FY2027 earnings at ($4.90) EPS.

Other research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Scribe Therapeutics to a "hold" rating in a report on Saturday, August 1st. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set an "overweight" rating and a $60.00 price target on the stock. Guggenheim started coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, Leerink Partners began coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They issued an "outperform" rating and a $37.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $51.75.

Scribe Therapeutics Trading Down 5.0%

SCTX opened at $29.00 on Wednesday. Scribe Therapeutics has a 1 year low of $17.31 and a 1 year high of $39.60.

Insider Buying and Selling

In related news, CFO David Parrot bought 2,666 shares of the stock in a transaction that occurred on Thursday, July 23rd. The stock was acquired at an average cost of $15.00 per share, with a total value of $39,990.00. Following the transaction, the chief financial officer directly owned 1,333 shares in the company, valued at approximately $19,995. This trade represents a -200.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Behzad Aghazadeh bought 7,905 shares of the business's stock in a transaction on Tuesday, July 28th. The shares were bought at an average cost of $18.25 per share, for a total transaction of $144,266.25. Following the completion of the acquisition, the director directly owned 3,088,888 shares in the company, valued at approximately $56,372,206. This trade represents a 0.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 3,727,237 shares of company stock valued at $56,291,746.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source